{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T02:08:42Z","timestamp":1775354922725,"version":"3.50.1"},"reference-count":41,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2019,3,30]]},"DOI":"10.1536\/ihj.18-035","type":"journal-article","created":{"date-parts":[[2019,2,21]],"date-time":"2019-02-21T17:36:46Z","timestamp":1550770606000},"page":"255-263","source":"Crossref","is-referenced-by-count":10,"title":["Efficacy of IntraCoronary Erythropoietin Delivery BEfore Reperfusion-Gauging Infarct Size in Patients with Acute ST-segment Elevation Myocardial Infarction (ICEBERG)"],"prefix":"10.1536","volume":"60","author":[{"given":"Won-Woo","family":"Seo","sequence":"first","affiliation":[{"name":"Division of Cardiology, Department of Internal Medicine, Kangdong Sacred Heart Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung-Won","family":"Suh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Il-Young","family":"Oh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Hwan","family":"Yoon","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Seok","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae-Jin","family":"Youn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In-Ho","family":"Chae","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-Ju","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Cardiovascular Center, Seoul National University Bundang Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-35.","DOI":"10.1056\/NEJMra071667"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Dominguez-Rodriguez A, Abreu-Gonzalez P, Reiter RJ. Cardioprotection and pharmacological therapies in acute myocardial infarction: Challenges in the current era. World J Cardiol 2014; 6: 100-6.","DOI":"10.4330\/wjc.v6.i3.100"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Fukui Y, Nozawa T, Ihori H, <i>et al<\/i>. Nicorandil attenuates ischemia-reperfusion injury via inhibition of norepinephrine release from cardiac sympathetic nerve terminals. Int Heart J 2017; 58: 787-93.","DOI":"10.1536\/ihj.16-391"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Wang Y, Wang Q, Yu W, Du H. Crocin attenuates oxidative stress and myocardial infarction injury in rats. Int Heart J 2018; 59: 387-93.","DOI":"10.1536\/ihj.17-114"},{"key":"5","doi-asserted-by":"publisher","unstructured":"5. Cai Z, Manalo DJ, Wei G, <i>et al<\/i>. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003; 108: 79-85.","DOI":"10.1161\/01.CIR.0000078635.89229.8A"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Rui T, Feng Q, Lei M, <i>et al<\/i>. Erythropoietin prevents the acute myocardial inflammatory response induced by ischemia\/reperfusion via induction of ap-1. Cardiovasc Res 2005; 65: 719-27.","DOI":"10.1016\/j.cardiores.2004.11.019"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. van der Meer P, Lipsic E, Henning RH, <i>et al<\/i>. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005; 46: 125-33.","DOI":"10.1016\/j.jacc.2005.03.044"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Suh JW, Chung WY, Kim YS, <i>et al<\/i>. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int J Cardiol 2011; 149: 216-20.","DOI":"10.1016\/j.ijcard.2010.02.002"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Ferrario M, Arbustini E, Massa M, <i>et al<\/i>. High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study. Int J Cardiol 2011; 147: 124-31.","DOI":"10.1016\/j.ijcard.2009.10.028"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Voors AA, Belonje AM, Zijlstra F, <i>et al<\/i>. A single dose of erythropoietin in ST-elevation myocardial infarction. Eur Heart J 2010; 31: 2593-600.","DOI":"10.1093\/eurheartj\/ehq304"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Binbrek AS, Rao NS, Al Khaja N, Assaqqaf J, Sobel BE. Erythropoietin to augment myocardial salvage induced by coronary thrombolysis in patients with ST-segment elevation acute myocardial infarction. Am J Cardiol 2009; 104: 1035-40.","DOI":"10.1016\/j.amjcard.2009.05.050"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Ott I, Schulz S, Mehilli J, <i>et al<\/i>. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention a randomized, double-blind trial. Circ Cardiovasc Interv 2010; 3: 408-13.","DOI":"10.1161\/CIRCINTERVENTIONS.109.904425"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Joy MS. Darbepoetin alfa: A novel erythropoiesis-stimulating protein. Ann Pharmacother 2002; 36: 1183-92.","DOI":"10.1345\/aph.1A416"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Voils SA, Harpe SH, Brophy GM. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness. Pharmacotherapy 2007; 27: 535-41.","DOI":"10.1592\/phco.27.4.535"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Lim GB. Antiplatelet therapy: Intracoronary abciximab during pci for STEMI. Nat Rev Cardiol 2012; 9: 258.","DOI":"10.1038\/nrcardio.2012.36"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Suh JW, Yoon YE, Oh IY, <i>et al<\/i>. A single-center prospective randomized controlled trial evaluating the safety and efficacy of intracoronary erythropoietin delivery before reperfusion: Gauging infarct size in patients with acute ST-segment elevation myocardial infarction. Study design and rationale of the &apos;ICEBERG Trial&apos;. Contemp Clin Trials 2013; 35: 145-50.","DOI":"10.1016\/j.cct.2013.03.001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Lip\u0161ic E, van der Meer P, Voors AA, <i>et al<\/i>. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: A randomized feasibility and safety study. Cardiovasc Drugs Ther 2006; 20: 135-41.","DOI":"10.1007\/s10557-006-7680-5"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Li J, Xu H, Gao Q, Wen Y. Effect of erythropoiesis-stimulating agents in acute ST-segment elevation myocardial infarction: A systematic review. Eur J Clin Pharmacol 2012; 68: 469-77.","DOI":"10.1007\/s00228-011-1160-y"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Moon C, Krawczyk M, Paik D, Lakatta EG, Talan MI. Cardioprotection by recombinant human erythropoietin following acute experimental myocardial infarction: Dose response and therapeutic window. Cardiovasc Drugs Ther 2005; 19: 243-50.","DOI":"10.1007\/s10557-005-3189-6"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. van&apos;t Hof AW, Liem A, Suryapranata H, Hoorntje JC, de Boer M-J, Zijlstra F. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute myocardial infarction: Myocardial blush grade. Circulation 1998; 97: 2302-6.","DOI":"10.1161\/01.CIR.97.23.2302"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kim D-W, Her S-H, Park M-W, <i>et al<\/i>. Impact of postprocedural TIMI flow on long-term clinical outcomes in patients with acute myocardial infarction. Int Heart J 2017; 58: 674-85.","DOI":"10.1536\/ihj.16-448"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Schr\u00f6der R, Dissmann R, Br\u00fcggemann T, <i>et al<\/i>. Extent of early ST segment elevation resolution: A simple but strong predictor of outcome in patients with acute myocardial infarction. J Am Coll Cardiol 1994; 24: 384-91.","DOI":"10.1016\/0735-1097(94)90292-5"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995; 27: 1281-92.","DOI":"10.1016\/S0022-2828(05)82390-9"},{"key":"24","doi-asserted-by":"crossref","unstructured":"25. Yoon CH, Chung WY, Suh JW, <i>et al<\/i>. Distal protection device aggravated microvascular obstruction evaluated by cardiac MR after primary percutaneous intervention for ST-elevation myocardial infarction. Int J Cardiol 2013; 167: 2002-7.","DOI":"10.1016\/j.ijcard.2012.05.029"},{"key":"25","doi-asserted-by":"crossref","unstructured":"26. Wright J, Adriaenssens T, Dymarkowski S, Desmet W, Bogaert J. Quantification of myocardial area at risk with T2-weighted CMR: Comparison with contrast-enhanced CMR and coronary angiography. JACC Cardiovasc Imaging 2009; 2: 825-31.","DOI":"10.1016\/j.jcmg.2009.02.011"},{"key":"26","doi-asserted-by":"crossref","unstructured":"27. Jelkmann W. Erythropoietin: Structure, control of production, and function. Physiol Rev 1992; 72: 449-89.","DOI":"10.1152\/physrev.1992.72.2.449"},{"key":"27","doi-asserted-by":"crossref","unstructured":"28. Brines M, Cerami A. Discovering erythropoietin&apos;s extra-hematopoietic functions: Biology and clinical promise. Kidney Int 2006; 70: 246-50.","DOI":"10.1038\/sj.ki.5001546"},{"key":"28","doi-asserted-by":"publisher","unstructured":"29. Cai Z, Semenza GL. Phosphatidylinositol-3-kinase signaling is required for erythropoietin-mediated acute protection against myocardial ischemia\/reperfusion injury. Circulation 2004; 109: 2050-3.","DOI":"10.1161\/01.CIR.0000127954.98131.23"},{"key":"29","doi-asserted-by":"crossref","unstructured":"30. Hearse D, Humphrey S, Chain E. Abrupt reoxygenation of the anoxic potassium-arrested perfused rat heart: A study of myocardial enzyme release. J Mol Cell Cardiol 1973; 5: 395-407.","DOI":"10.1016\/0022-2828(73)90030-8"},{"key":"30","doi-asserted-by":"crossref","unstructured":"31. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004; 61: 481-97.","DOI":"10.1016\/j.cardiores.2003.10.011"},{"key":"31","doi-asserted-by":"crossref","unstructured":"32. Hirata A, Minamino T, Asanuma H, <i>et al<\/i>. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 2006; 48: 176-84.","DOI":"10.1016\/j.jacc.2006.04.008"},{"key":"32","doi-asserted-by":"crossref","unstructured":"33. Riksen NP, Hausenloy DJ, Yellon DM. Erythropoietin: Ready for prime-time cardioprotection. Trends Pharmacol Sci 2008; 29: 258-67.","DOI":"10.1016\/j.tips.2008.02.002"},{"key":"33","doi-asserted-by":"crossref","unstructured":"34. Najjar SS, Rao SV, Melloni C, <i>et al<\/i>. Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: Reveal: A randomized controlled trial. JAMA 2011; 305: 1863-72.","DOI":"10.1001\/jama.2011.592"},{"key":"34","doi-asserted-by":"crossref","unstructured":"35. Ott I, Schulz S, Mehilli J, <i>et al<\/i>. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary interventionclinical perspective: A randomized, double-blind trial. Circ Cardiovasc Interv 2010; 3: 408-13.","DOI":"10.1161\/CIRCINTERVENTIONS.109.904425"},{"key":"35","doi-asserted-by":"crossref","unstructured":"36. Gao D, Ning N, Niu X, <i>et al<\/i>. Erythropoietin treatment in patients with acute myocardial infarction: A meta-analysis of randomized controlled trials. Am Heart J 2012; 164: 715-27.e711.","DOI":"10.1016\/j.ahj.2012.07.031"},{"key":"36","doi-asserted-by":"crossref","unstructured":"37. Roubille F, Prunier F, Barr\u00e8re-Lemaire S, <i>et al<\/i>. What is the role of erythropoietin in acute myocardial infarct? Bridging the gap between experimental models and clinical trials. Cardiovasc Drugs Ther 2013; 27: 315.","DOI":"10.1007\/s10557-013-6461-1"},{"key":"37","doi-asserted-by":"crossref","unstructured":"38. Roubille F, Micheau A, Combes S, <i>et al<\/i>. Intracoronary administration of darbepoetin-alpha at onset of reperfusion in acute myocardial infarction: Results of the randomized Intra-Co-EpoMI trial. Arch Cardiovasc Dis 2013; 106: 135-45.","DOI":"10.1016\/j.acvd.2012.12.001"},{"key":"38","doi-asserted-by":"publisher","unstructured":"39. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction. Circulation 2000; 101: 2981-8.","DOI":"10.1161\/01.CIR.101.25.2981"},{"key":"39","doi-asserted-by":"crossref","unstructured":"40. Nishiya D, Omura T, Shimada K, <i>et al<\/i>. Effects of erythropoietin on cardiac remodeling after myocardial infarction. J Pharmacol Sci 2006; 101: 31-9.","DOI":"10.1254\/jphs.FP0050966"},{"key":"40","doi-asserted-by":"crossref","unstructured":"41. Wen Y, Xu J, Ma X, Gao Q. High-dose erythropoietin in acute ST-segment elevation myocardial infarction: A meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs 2013; 13: 435-42.","DOI":"10.1007\/s40256-013-0042-3"},{"key":"41","doi-asserted-by":"crossref","unstructured":"42. Fokkema ML, Kleijn L, van der Meer P, <i>et al<\/i>. Long term effects of epoetin alfa in patients with ST-elevation myocardial infarction. Cardiovasc Drugs Ther 2013; 27: 433-9.","DOI":"10.1007\/s10557-013-6470-0"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/2\/60_18-035\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,23]],"date-time":"2019-03-23T23:34:30Z","timestamp":1553384070000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/2\/60_18-035\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,30]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.18-035","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,30]]}}}